Abstracts tagged "fatigue and quality of life"

Abstract Number: 2384 • 2019 ACR/ARP Annual Meeting
Yoga Improves Fatigue and Mental Health in Rheumatoid Arthritis: Preliminary Results of a Randomized Controlled Trial
Silva Pukšić¹, Joško Mitrović ², Melanie-Ivana Čulo ², Marcela Živković ³, Biserka Orehovec ⁴, Dubravka Bobek ⁵, Marko Lucijanić ⁶ and Jadranka Morović-Vergles ⁷, ¹Department of Clinical Immunology, Rheumatology and Allergology, University Hospital Dubrava, Zagreb, Croatia, Zagreb, Croatia, ²Department of Clinical Immunology, Rheumatology and Allergology, University Hospital Dubrava, Zagreb, Croatia, ³Department of Laboratory Diagnostics, University Hospital Dubrava, Zagreb, Croatia, Zagreb, Croatia, ⁴Department of Laboratory Diagnostics, University Hospital Dubrava, Zagreb, Croatia, ⁵Department of Physical Medicine and Rehabilitation with Rheumatology, University Hospital Dubrava, Zagreb, Croatia, Zagreb, Croatia, ⁶Department of Hematology, University Hospital Dubrava, Zagreb, Croatia, Zagreb, Croatia, ⁷Department of Clinical Immunology, Rheumatology and Allergology, University Hospital Dubrava, School of Medicine,Zagreb, Croatia, Zagreb, Croatia
Background/Purpose: Rheumatoid arthritis (RA) patients perceive reduced health-related quality of life (HRQOL) through functional disability, pain, increased fatigue and impaired psychological functioning. Previous trials demonstrated…
Abstract Number: 1786 • 2015 ACR/ARHP Annual Meeting
Improvements in Health-Related Quality of Life and Fatigue Following Administration of an IL-6 Monoclonal Antibody (PF-04236921) in an Enriched Population of Subjects with Active SLE
Vibeke Strand¹, Annette Diehl², Jared Christensen², Joseph Wajdula², Sudhakar Sridharan³ and Paul J Healey², ¹Biopharmaceutical Consultant, Portola Valley, CA, ²Pfizer Inc, New York City, NY, ³PPD Inc, Rockville, MA
Background/Purpose: The 10 mg dose of PF-04236921 showed evidence of efficacy in a phase 2 randomized controlled trial (RCT) in SLE.1,2 Here patient-reported outcomes (PROs)…
Abstract Number: 2282 • 2015 ACR/ARHP Annual Meeting
“Doing Every-Day Life” with Primary Sjögren’s Syndrome: Factors Predicting Difficulties Performing Daily Activities and Taking on Life Roles
Katie Hackett¹, Dennis W Lendrem², Tim Rapley³, Katherine Deane⁴, Vincent Deary⁵, Simon Bowman⁶, Julia Newton⁷, Wan-Fai Ng⁸ and on behalf of the United Kingdom Primary Sjogren's Syndrome Registry, ¹Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ²Institute of Cellular Medicine (Musculoskeletal Research Group), NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, ³Institute of Health and Society, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁴University of East Anglia, Norwich, United Kingdom, ⁵School of Health Psychology, Northumbia University, Newcastle upon Tyne, United Kingdom, ⁶Rheumatology Dept, University Hospital Birmingham, Birmingham, United Kingdom, ⁷Newcastle University, Newcastle upon Tyne, United Kingdom, ⁸Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
Background/Purpose: Primary Sjögren’s Syndrome (pSS) is an autoimmune disease which targets secretory glands and results in dryness. In addition pSS patients frequently experience symptoms of…
Abstract Number: 1104 • 2013 ACR/ARHP Annual Meeting
Quality Of Life and Burden Of Ehlers-Danlos Syndrome (EDS) Type III
Marion Geoffroy¹, Christelle Guillaume¹, Amélie Servettaz¹, Violaine Laurant-Noel¹, Christine Serratrice Sr.², Jacques Serratrice³, Boris Bienvenu⁴ and Roland Jaussaud⁵, ¹Médecine interne, maladies infectieuses, immunologie clinique, Hôpital Robert Debré. CHU de Reims, Reims, France, ²internal medicine, Foundation Hopital Saint Joseph, Marseille, France, ³Hôpital de la Timone, Marseille, France, ⁴Division of Internal Medicine, Centre Hospitalier Régional Universitaire de Caen, Côte de Nacre, Caen, France, Caen, France, ⁵Médecine interne, maladies infectieuses, immunologie clinique, CHU de Reims, REIMS, France
Background/Purpose: The Ehlers-Danlos syndrome (EDS) is a clinically and genetically heterogeneous group of inherited connective tissue disorders. Hypermobility type EDS is the most common type…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].